{"id":75711,"date":"2023-10-23T03:42:52","date_gmt":"2023-10-23T07:42:52","guid":{"rendered":"https:\/\/ifintechworld.com\/news\/united-therapeutics-shifts-focus-to-tyvaso-dpi-amidst-generic-threat-nasdaquthr\/"},"modified":"2023-10-23T03:42:56","modified_gmt":"2023-10-23T07:42:56","slug":"united-therapeutics-shifts-focus-to-tyvaso-dpi-amidst-generic-threat-nasdaquthr","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=75711","title":{"rendered":"United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat (NASDAQ:UTHR)"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

At a Glance<\/h2>\n

United Therapeutics’<\/strong> (NASDAQ:UTHR<\/span>) Q2 performance underscores robust financials with a notable 27.7% YoY revenue increase, fueling investor optimism. On the clinical front, the transition to Tyvaso DPI (Dry Powder Inhaler) reveals a calculated strategic pivot aimed at retaining and possibly expanding market share in the face of looming generic competition. While the company’s ample liquidity and strong cash flow mitigate the near-term need for external financing, the potential for market share erosion as generics enter the fray necessitates vigilance. Equally, United’s ongoing patent dispute and the mixed signals from insider activity require careful scrutiny. These factors, when considered alongside strategic endeavors like production scaling and physician outreach, create a complex tableau that investors should navigate cautiously.<\/span><\/p>\n

United’s Q2 Earnings<\/h2>\n

To begin my analysis, looking at United’s most recent earnings report for Q2 2023, total revenues increased to $596.5M, up from $466.9M YoY, a significant 27.7% surge. Operating income rose sharply to $313.4M from $201.8M YoY, highlighting robust operational control despite total operating expenses marginally increasing to $283.1M from $265.1M YoY. Cost of sales exhibited a more than twofold rise to $64.1M, suggesting pressure on margins. Notably, share dilution remains subdued with diluted shares increasing modestly to 49.5M from 48.1M YoY.<\/span><\/p>\n

In the Q2 2023 breakdown of net product sales, Tyvaso (treprostinil inhalation) generated $318.9M, marking a 59% YoY increase (with DPI contributing $96.9 million). Remodulin recorded $127.2M, a 4% YoY decrease. Orenitram accounted for $95.1M, up 20% YoY. Unituxin stood at $44.3M, virtually unchanged from last year. Adcirca brought in $7.5M, a 28% YoY decline. The ‘Other’ category added $3.5M.<\/p>\n

Financial Health<\/h2>\n

Turning to United’s balance sheet, as of June 30, 2023, the company held $1.07B in ‘Cash and cash equivalents’ and an additional $1.61B in ‘Marketable investments’, totaling to $2.68B in highly liquid assets. The current ratio, calculated by dividing the total current assets of $3.21B by the total current liabilities of $370.3M, stands robust at 8.68. The company’s total assets of $6.68B far outweigh its total debt obligations, including a line of credit of $800M, totaling $1.27B.<\/p>\n

Over the last six months, United generated a net cash of $481.1M from operating activities, translating to approximately $80.2M per month. In light of the substantial liquidity, a solid current ratio, and a positive operating cash flow, the odds of United requiring additional external financing within the next twelve months appear low.<\/p>\n

Market Sentiment<\/h2>\n

According to Seeking Alpha data, United’s $10.58B market cap aligns with its robust financial health, signaling market confidence. Growth prospects are promising; analysts project YoY revenue increases from $2.26B in 2023 to $2.77B by 2025, backed by strategic advancements like Tyvaso DPI. Comparing stock momentum to SPY, UTHR underperforms in the short term but has shown some resilience with a 1Y return of +4.44% versus SPY’s +15.23%, suggesting investor cautiousness.<\/p>\n

Technically, UTHR trades near the 50-day moving average (227.60) and below the 200-day moving average (232.12), indicating a cautious bearish bias. The RSI at 45.55 suggests a neutral momentum. Volume trends are consistent without notable spikes. The MACD line hovers above the signal line but is showing signs of potential convergence, which may hint at a short-term trend reversal. Immediate resistance is near the 200-day moving average.<\/p>\n

\n

\"Chart\" <\/picture>
\n

StockCharts.com<\/span><\/p>\n<\/figcaption><\/figure>\n<\/p>\n

A low short interest of 2.23% indicates limited bearish sentiment. Institutional ownership<\/strong> stands at 95.22%, with new positions at 895,306 shares and sold-out positions at 867,712 shares; major holders include BlackRock and Wellington Management. Insider activity<\/strong> shows a net sale of 38,383 shares over 3 months and 1,212,809 over 12 months, signaling potential caution among insiders.<\/p>\n

Patent Dispute Could Reshape United’s Tyvaso Market<\/h2>\n

The patent dispute between Liquidia<\/strong> (LQDA) and United revolves around U.S. Patent No. 10,716,793, concerning a method of administering treprostinil via inhalation\u200b. The dispute escalated in September when United filed a patent infringement action under the Hatch-Waxman Act, claiming that Liquidia’s New Drug Application infringed three of its patents\u200b.<\/p>\n

Liquidia intends to market an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH), competing with United’s Tyvaso. The FDA granted tentative approval for Liquidia’s generic, paving the way for potential market entry as Yutrepia for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in March 2024\u200b\u200b.<\/p>\n

The legal saga saw various developments, including a reaffirmation by the Patent Trial and Appeal Board (PTAB) to invalidate all claims of the ‘793 patent, though a federal appeals court later sided with United, maintaining Liquidia’s infringement\u200b\u200b.<\/p>\n

The implications for United investors are manifold. The enforcement of patent rights can shield United from competition, safeguarding its market share and revenue streams from Tyvaso. On the flip side, a ruling in favor of Liquidia could have opened the door to generic competition sooner than anticipated, potentially eroding United’s market share and impacting its stock price. The stock prices of both companies have been reactive to the developments in the dispute, as seen on a particular day when Liquidia’s shares closed down 12.76% and United’s shares were down about 1%\u200b\u200b.<\/p>\n

Dose of Convenience: How Tyvaso DPI Outpaces Its Predecessor<\/h2>\n

United has transitioned to Tyvaso DPI amidst the looming threat of generic competition for its original formulation, Tyvaso Inhalation Solution. This transition is part of a broader strategy to sustain and bolster its market share in the treatment of PAH and PH-ILD\u200b\u200b. Here are several factors and evidence that might suggest Tyvaso DPI could have a competitive edge over a cheaper generic version of Tyvaso:<\/p>\n

Improved Formulation:<\/strong><\/p>\n